A patient with chronic granulomatous disease has been treated with a type of genome editing called prime editing, in a world first for this approach, which allows precise corrections to be made to the genome without double-stranded breaks (see BioNews 1021 and 1243).
Dr Harry Malech, a researcher from the National Institites of Health in Bethesda, Maryland, and investigator on the study, announced the (unpublished) medical breakthrough during an award speech at the American Society of Gene and Cell Therapy meeting.
For more information, see STAT News.